Bio-Path Holdings, Inc.
BPTH
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Bio-Path Holdings, Inc. is a preclinical-stage biotechnology company whose core business model involves conducting animal testing to develop its drug candidates. The company’s primary assets, including its lead compound prexigebersen, are advanced through preclinical studies that require the use of animals to assess toxicity and efficacy.
The company is flagged by Cruelty Free Investing for its exploitation of animals in pre-clinical trials. This activity is central to its research and development pipeline, as the company has no market-approved products and relies on animal data to advance its investigational therapies toward human clinical trials.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.